Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Analog
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Mira Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
MIRA Pharmaceuticals Announces Collaboration with Pharmaseed
Details : The collaboration aims to assist MIRA in the research and development of Ketamir-2 (ketamir analog), which aids individuals struggling with major depressive disorder with suicidal ideation.
Brand Name : Ketamir-2
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 08, 2024
Lead Product(s) : Ketamine Analog
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Mira Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?